ATE531368T1 - Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung - Google Patents

Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung

Info

Publication number
ATE531368T1
ATE531368T1 AT04762794T AT04762794T ATE531368T1 AT E531368 T1 ATE531368 T1 AT E531368T1 AT 04762794 T AT04762794 T AT 04762794T AT 04762794 T AT04762794 T AT 04762794T AT E531368 T1 ATE531368 T1 AT E531368T1
Authority
AT
Austria
Prior art keywords
tacrolimus
modified release
compositions containing
release compositions
release agents
Prior art date
Application number
AT04762794T
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Original Assignee
Veloxis Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veloxis Pharmaceuticals As filed Critical Veloxis Pharmaceuticals As
Priority claimed from PCT/DK2004/000573 external-priority patent/WO2005020993A1/en
Application granted granted Critical
Publication of ATE531368T1 publication Critical patent/ATE531368T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04762794T 2003-08-29 2004-08-30 Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung ATE531368T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301232 2003-08-29
DKPA200301837 2003-12-11
US52979303P 2003-12-15 2003-12-15
DKPA200400079 2004-01-21
DKPA200400463 2004-03-23
DKPA200400467 2004-03-23
PCT/DK2004/000573 WO2005020993A1 (en) 2003-08-29 2004-08-30 Modified release compositions comprising tacrolimus

Publications (1)

Publication Number Publication Date
ATE531368T1 true ATE531368T1 (de) 2011-11-15

Family

ID=42994769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762794T ATE531368T1 (de) 2003-08-29 2004-08-30 Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung

Country Status (8)

Country Link
US (1) US8591946B2 (de)
JP (1) JP4903568B2 (de)
CN (2) CN1859909B (de)
AT (1) ATE531368T1 (de)
DK (2) DK1663216T3 (de)
ES (1) ES2376238T3 (de)
PT (2) PT1663217E (de)
SI (2) SI1663216T1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020994A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
EP1868576A2 (de) * 2005-03-17 2007-12-26 Elan Pharma International Limited Injizierbare zusammensetzungen von nanoteilchenförmigen immunsuppressiven verbindungen
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
WO2008084698A1 (ja) * 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
ES2435197T3 (es) 2007-01-10 2013-12-16 Board Of Regents, The University Of Texas System Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar
MX2009010556A (es) 2007-03-29 2009-10-22 Panacea Biotec Ltd Formas de dosificacion modificada de tacrolimus.
LT2167033T (lt) * 2007-05-30 2017-08-10 Veloxis Pharmaceuticals A/S Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
US12083103B2 (en) * 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
US8349033B2 (en) * 2007-05-31 2013-01-08 The Penray Companies, Inc. Diesel fuel, diesel fuel additive, and associated method for using the same
WO2009040818A1 (en) 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US8222272B2 (en) * 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
WO2010005980A1 (en) * 2008-07-08 2010-01-14 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
KR101174183B1 (ko) 2008-11-28 2012-08-16 주식회사 삼양바이오팜 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법
WO2011071805A1 (en) * 2009-12-07 2011-06-16 Raptor Pharmaceuticals Inc. 4-methylpyrazole formulations
EP2521537A2 (de) * 2010-01-04 2012-11-14 Wockhardt Limited Pharmazeutische zusammensetzung zur modifizierten freisetzung von wirkstoffen
RS55118B1 (sr) 2010-02-17 2016-12-30 Veloxis Pharmaceuticals As Stabilizovana takrolimus kompozicija
EA201291097A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Финголимод в форме гранулированного расплава
CA2797042A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EP2768537B1 (de) * 2011-10-18 2019-02-20 Purdue Pharma LP Acrylpolymerformulierungen
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
US20170072058A1 (en) 2014-11-21 2017-03-16 Solipharma Llc Pharmaceutical composition containing tacrolimus and preparation methods thereof
BR112018006406B1 (pt) * 2015-10-23 2022-01-18 Basf Se Formulação odorante e aromatizante, e, uso de uma formulação
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
CN106309395B (zh) * 2016-09-22 2019-09-20 沈阳药科大学 一种他克莫司缓释片及其制备方法
CN107595799A (zh) * 2017-10-30 2018-01-19 无锡福祈制药有限公司 一种复方肠溶口崩片及其制备方法
WO2020076453A1 (en) * 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
JPWO2021157569A1 (de) * 2020-02-03 2021-08-12
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114469847B (zh) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
JP3520517B2 (ja) * 1992-11-18 2004-04-19 藤沢薬品工業株式会社 医薬用持続性製剤
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
RU2214244C9 (ru) * 1998-03-26 2020-07-29 Астеллас Фарма Инк. Препараты с замедленным высвобождением
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2001078681A1 (fr) 2000-04-17 2001-10-25 Yamanouchi Pharmaceutical Co., Ltd. Systeme d'administration de medicament empechant l'interaction pharmacocinetique entre les medicaments et procede correspondant
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1289560A1 (de) 2000-06-12 2003-03-12 SmithKline Beecham Corporation Neue feste dispersionszusammensetzungen
US6367913B1 (en) * 2000-10-31 2002-04-09 Hewlett-Packard Company System and method for improving the lightfastness of color printouts
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
AU2002325192B2 (en) 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
WO2005004848A1 (en) 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
US20070122482A1 (en) * 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
JP2007526341A (ja) * 2004-03-03 2007-09-13 スフェリックス， インコーポレイテッド 疎水性薬物のためのポリマー薬物送達システム
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
EP1868576A2 (de) * 2005-03-17 2007-12-26 Elan Pharma International Limited Injizierbare zusammensetzungen von nanoteilchenförmigen immunsuppressiven verbindungen

Also Published As

Publication number Publication date
CN1859909B (zh) 2011-04-06
DK1663216T3 (da) 2012-02-20
DK1663217T3 (da) 2010-11-08
CN1859909A (zh) 2006-11-08
PT1663217E (pt) 2010-10-18
US20060287352A1 (en) 2006-12-21
PT1663216E (pt) 2012-02-14
US8591946B2 (en) 2013-11-26
SI1663216T1 (sl) 2012-03-30
JP4903568B2 (ja) 2012-03-28
SI1663217T1 (sl) 2010-10-29
CN101869561A (zh) 2010-10-27
ES2376238T3 (es) 2012-03-12
JP2007504103A (ja) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE531368T1 (de) Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
PL1663216T3 (pl) Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2010081824A3 (en) Active coating of pharmaceutical dosage forms
RS52891B (en) GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
BG105061A (en) Enteric coated pharmaceutical composition and method of manufacturing
ATE522204T1 (de) Beschichtete pellets
WO2009090558A3 (en) Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2005118166A3 (en) Pharmaceutical composition containing irbesartan
WO2006085335A3 (en) Pharmaceutical composition of acid labile substances
FR2842736B1 (fr) Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
PL1713446T3 (pl) Nielamelarne trójskładnikowe kompozycje lipidów
WO2007022022A3 (en) Volumizing agents
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
WO2008039472A3 (en) Stabilizing compositions for antibiotics and methods of use
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
WO2008105808A3 (en) FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
DK1677777T3 (da) Pellets indeholdende venlafaxin-hydrochlorid
BRPI0510694A (pt) composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole
BRPI0011404B8 (pt) microgrânulos de sulfato de morfina de liberação prolongada, processo de preparação dos mesmos e composição farmacêutica.
WO2005002553A3 (en) Fluconazole capsules with improved release
DK1847258T3 (da) Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thie-no[3,2-c]pyridin-derivater
ITMI20040498A1 (it) Composizioni granulari